
|Articles|April 15, 2003
Antibiotic combats acute bacterial conjunctivitis
Andover, MA-The antibiotic ISV-401 (InSite Vision, Alameda, CA) in development to treat acute bacterial conjunctivitis has achieved a bacterial eradication rate of 85% by the third day of treatment and 90% by 7 to 9 days, according to a phase II clinical trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
3
Glaucoma innovation: Eight themes to watch in 2026
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5












































